ID

43022

Description

Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication; ODM derived from: https://clinicaltrials.gov/show/NCT01805531

Lien

https://clinicaltrials.gov/show/NCT01805531

Mots-clés

Versions (2)
  1. 07/08/2019 07/08/2019 -
  2. 17/09/2021 17/09/2021 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

17 septembre 2021

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Atrial Fibrillation NCT01805531

Anglais

Eligibility Atrial Fibrillation NCT01805531

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
female and male subjects ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation
Description

Age | Atrial Fibrillation

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0004238
who are treated with vitamin k antagonists (vka) with issues for at least the 4 previous weeks (issues are assessed on medical judgment)
Description

Treatment with Vitamin K antagonist | Problem Duration

Type de données

boolean

Alias
UMLS CUI [1]
C1096489
UMLS CUI [2,1]
C0033213
UMLS CUI [2,2]
C0449238
who start treatment with rivaroxaban to prevent stroke or non-cns (central nervous system) systemic embolism
Description

rivaroxaban | Treatment Preventing Cerebrovascular accident | Treatment Preventing SYSTEMIC ARTERIAL EMBOLISM | Exception Central Nervous System

Type de données

boolean

Alias
UMLS CUI [1]
C1739768
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C1292733
UMLS CUI [2,3]
C0038454
UMLS CUI [3,1]
C0087111
UMLS CUI [3,2]
C1292733
UMLS CUI [3,3]
C0149876
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C3714787
with anticoagulation therapy planned for at least 6 months
Description

Anticoagulation Therapy Planned

Type de données

boolean

Alias
UMLS CUI [1,1]
C0003281
UMLS CUI [1,2]
C1301732
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
contra indication to the use of xarelto as described in the summary of product characteristics (smpc); key contra indications are:
Description

Medical contraindication Xarelto

Type de données

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C3159309
hypersensitivity to the active substance or to any of the excipients listed in smpc section 6.1.
Description

Hypersensitivity Xarelto | Hypersensitivity Xarelto Excipient

Type de données

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C3159309
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C3159309
UMLS CUI [2,3]
C0015237
lesion or condition at significant risk of major bleeding
Description

Lesion At risk Hemorrhage Major | Condition At risk Hemorrhage Major

Type de données

boolean

Alias
UMLS CUI [1,1]
C0221198
UMLS CUI [1,2]
C1444641
UMLS CUI [1,3]
C0019080
UMLS CUI [1,4]
C0205164
UMLS CUI [2,1]
C0348080
UMLS CUI [2,2]
C1444641
UMLS CUI [2,3]
C0019080
UMLS CUI [2,4]
C0205164
concomitant treatment with any other anticoagulant agent
Description

Anticoagulants Other

Type de données

boolean

Alias
UMLS CUI [1,1]
C0003280
UMLS CUI [1,2]
C0205394
clinically significant active bleeding
Description

Hemorrhage

Type de données

boolean

Alias
UMLS CUI [1]
C0019080
hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with child pugh b and c
Description

Liver disease Associated with Blood Coagulation Disorders | Bleeding risk | Patients Cirrhotic Child-Pugh Classification

Type de données

boolean

Alias
UMLS CUI [1,1]
C0023895
UMLS CUI [1,2]
C0332281
UMLS CUI [1,3]
C0005779
UMLS CUI [2]
C3251812
UMLS CUI [3,1]
C0030705
UMLS CUI [3,2]
C0439686
UMLS CUI [3,3]
C4050412
pregnancy and breast feeding
Description

Pregnancy | Breast Feeding

Type de données

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
Retour au début de la page

Similar models

Eligibility Atrial Fibrillation NCT01805531

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Age | Atrial Fibrillation
Item
female and male subjects ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation
boolean
C0001779 (UMLS CUI [1])
C0004238 (UMLS CUI [2])
Treatment with Vitamin K antagonist | Problem Duration
Item
who are treated with vitamin k antagonists (vka) with issues for at least the 4 previous weeks (issues are assessed on medical judgment)
boolean
C1096489 (UMLS CUI [1])
C0033213 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
rivaroxaban | Treatment Preventing Cerebrovascular accident | Treatment Preventing SYSTEMIC ARTERIAL EMBOLISM | Exception Central Nervous System
Item
who start treatment with rivaroxaban to prevent stroke or non-cns (central nervous system) systemic embolism
boolean
C1739768 (UMLS CUI [1])
C0087111 (UMLS CUI [2,1])
C1292733 (UMLS CUI [2,2])
C0038454 (UMLS CUI [2,3])
C0087111 (UMLS CUI [3,1])
C1292733 (UMLS CUI [3,2])
C0149876 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C3714787 (UMLS CUI [4,2])
Anticoagulation Therapy Planned
Item
with anticoagulation therapy planned for at least 6 months
boolean
C0003281 (UMLS CUI [1,1])
C1301732 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Medical contraindication Xarelto
Item
contra indication to the use of xarelto as described in the summary of product characteristics (smpc); key contra indications are:
boolean
C1301624 (UMLS CUI [1,1])
C3159309 (UMLS CUI [1,2])
Hypersensitivity Xarelto | Hypersensitivity Xarelto Excipient
Item
hypersensitivity to the active substance or to any of the excipients listed in smpc section 6.1.
boolean
C0020517 (UMLS CUI [1,1])
C3159309 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C3159309 (UMLS CUI [2,2])
C0015237 (UMLS CUI [2,3])
Lesion At risk Hemorrhage Major | Condition At risk Hemorrhage Major
Item
lesion or condition at significant risk of major bleeding
boolean
C0221198 (UMLS CUI [1,1])
C1444641 (UMLS CUI [1,2])
C0019080 (UMLS CUI [1,3])
C0205164 (UMLS CUI [1,4])
C0348080 (UMLS CUI [2,1])
C1444641 (UMLS CUI [2,2])
C0019080 (UMLS CUI [2,3])
C0205164 (UMLS CUI [2,4])
Anticoagulants Other
Item
concomitant treatment with any other anticoagulant agent
boolean
C0003280 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
Hemorrhage
Item
clinically significant active bleeding
boolean
C0019080 (UMLS CUI [1])
Liver disease Associated with Blood Coagulation Disorders | Bleeding risk | Patients Cirrhotic Child-Pugh Classification
Item
hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with child pugh b and c
boolean
C0023895 (UMLS CUI [1,1])
C0332281 (UMLS CUI [1,2])
C0005779 (UMLS CUI [1,3])
C3251812 (UMLS CUI [2])
C0030705 (UMLS CUI [3,1])
C0439686 (UMLS CUI [3,2])
C4050412 (UMLS CUI [3,3])
Pregnancy | Breast Feeding
Item
pregnancy and breast feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial